Evan Friedman

702 total citations
22 papers, 555 citations indexed

About

Evan Friedman is a scholar working on Oncology, Infectious Diseases and Virology. According to data from OpenAlex, Evan Friedman has authored 22 papers receiving a total of 555 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 7 papers in Infectious Diseases and 6 papers in Virology. Recurrent topics in Evan Friedman's work include HIV/AIDS drug development and treatment (7 papers), HIV Research and Treatment (6 papers) and Pharmacogenetics and Drug Metabolism (4 papers). Evan Friedman is often cited by papers focused on HIV/AIDS drug development and treatment (7 papers), HIV Research and Treatment (6 papers) and Pharmacogenetics and Drug Metabolism (4 papers). Evan Friedman collaborates with scholars based in United States, Canada and Belgium. Evan Friedman's co-authors include Marian Iwamoto, John A. Wagner, Eric H. Rubin, Nancy Agrawal, Keith Gottesdiener, Larissa Wenning, Julie A. Stone, Sheila Breidinger, S. Aubrey Stoch and Punam Sandhu and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.

In The Last Decade

Evan Friedman

21 papers receiving 540 citations

Peers

Countries citing papers authored by Evan Friedman

Since Specialization

Citations

This map shows the geographic impact of Evan Friedman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Evan Friedman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Evan Friedman more than expected).

Fields of papers citing papers by Evan Friedman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Evan Friedman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Evan Friedman. The network helps show where Evan Friedman may publish in the future.

Co-authorship network of co-authors of Evan Friedman

This figure shows the co-authorship network connecting the top 25 collaborators of Evan Friedman. A scholar is included among the top collaborators of Evan Friedman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Evan Friedman. Evan Friedman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Variability of Parkinsonian Tremor During Different Tasks and Under External Interference 2024 ·IEEE Sensors Journal ·(unknown), Yue Zhou, Mary E. Jenkins, S. Jayne Garland, Evan Friedman, Michael D. Naish, Ana Luisa Trejos	0
2	Tremor Suppression Using Functional Electrical Stimulation 2024 ·IEEE Transactions on Neural Systems and Rehabilitation Engineering ·(unknown), Yue Zhou, Mary E. Jenkins, S. Jayne Garland, Evan Friedman, Michael D. Naish, Ana Luisa Trejos	6
3	991O First-in-human (FIH) phase I data of HST-1011, an oral CBL-B inhibitor, in patients with advanced solid tumors 2024 ·Annals of Oncology ·Rachel E. Sanborn, Minal Patel, Jordi Rodón, (unknown), (unknown), David Levitz, (unknown), Amy Goodman, Parul Agarwal, Evan Friedman, Hadi Danaee, Kimberly A. Robell, Samira Jaeger, (unknown), (unknown), Jeffrey H. Dunn, (unknown), Timothy Reilly, Jason J. Luke, Amanda J. Redig	1
4	Abstract CT251: Phase 1/2 study of HST-1011, an oral CBL-B inhibitor, alone and in combination with anti-PD1 in patients with advanced solid tumors 2023 ·Cancer Research ·Jason J. Luke, Rachel E. Sanborn, Jordi Rodón, Manish R. Patel, Parul Agarwal, Evan Friedman, (unknown), Heather H. Kelley, (unknown), Hadi Danaee, (unknown), (unknown), Timothy Reilly, Amanda J. Redig, Claire F. Friedman	2
5	Safety, tolerability, and pharmacokinetics of single‐ and multiple‐dose administration of islatravir (MK‐8591) in adults without HIV 2021 ·Clinical and Translational Science ·Randolph P. Matthews, (unknown), Evan Friedman, Deanne Jackson Rudd, Yang Liu, Robin Mogg, Deborah Panebianco, Inge De Lepeleire, (unknown), Jay A. Grobler, S. Aubrey Stoch, Marian Iwamoto	29
6	Thorough QTc Study of a Single Supratherapeutic Dose of Relebactam in Healthy Participants 2020 ·Clinical Pharmacology in Drug Development ·(unknown), Yang Liu, (unknown), Terry O’Reilly, Francheska Colón‐González, Evan Friedman, Mallika Lala, Elizabeth G. Rhee, Matthew L. Rizk	3
7	Safety, pharmacokinetics, and antiretroviral activity of islatravir (ISL, MK-8591), a novel nucleoside reverse transcriptase translocation inhibitor, following single-dose administration to treatment-naive adults infected with HIV-1: an open-label, phase 1b, consecutive-panel trial 2020 ·The Lancet HIV ·Dirk Schürmann, Deanne Jackson Rudd, (unknown), Inge De Lepeleire, Martine Robberechts, Evan Friedman, Christian Keicher, Andreas Hüser, Jörg Hofmann, Jay A. Grobler, S. Aubrey Stoch, Marian Iwamoto, Randolph P. Matthews	62
8	Performance Evaluation of EEG/EMG Fusion Methods for Motion Classification 2019 ·PubMed ·(unknown), Evan Friedman, Ana Luisa Trejos	22
9	Novel Gastroretentive Controlled Release Formulations for Once-Daily Administration: Assessment of Clinical Feasibility and Formulation Concept for Raltegravir 2016 ·Therapeutic Innovation & Regulatory Science ·Rajesh Krishna, Matthew L. Rizk, Patrick Larson, Valerie Schulz, Evan Friedman, Pranav Gupta, (unknown), Alyson Connor, John McDermott, Ronald L. Smith, Philip Evans	2
10	Single and multiple dose pharmacokinetics and pharmacodynamics of omarigliptin, a novel, once‐weekly dipeptidyl peptidase‐4 inhibitor, in healthy Japanese men 2016 ·Journal of Diabetes Investigation ·(unknown), Evan Friedman, Carol Addy, (unknown), Daniel Tatosian, Yuki Matsumoto, Hideyo Suzuki, Eunkyung Kauh	21
11	Phase 2 study of programmed death-1 antibody (anti-PD-1, MK-3475) in patients with microsatellite unstable (MSI) tumors. 2014 ·Journal of Clinical Oncology ·Dung T. Le, Nilofer S. Azad, Dan Laheru, Ilene Browner, Hao Wang, Jennifer N. Uram, Holly Kemberling, Lei Zheng, Robert Iannone, Evan Friedman, Amy Meister, Ross C. Donehower, Ana De Jesus‐Acosta, Luis A. Díaz	4
12	Clinical pharmacology profile of vorinostat, a histone deacetylase inhibitor 2013 ·Cancer Chemotherapy and Pharmacology ·Marian Iwamoto, Evan Friedman, Punam Sandhu, Nancy Agrawal, Eric H. Rubin, John A. Wagner	58
13	Effect of Different Durations and Formulations of Diltiazem on the Single-Dose Pharmacokinetics of Midazolam: How Long Do We Go? 2011 ·The Journal of Clinical Pharmacology ·Evan Friedman, Iain P. Fraser, Yinghong Wang, Arthur Bergman, Chi‐Chung Li, Patrick Larson, Jeffrey Chodakewitz, John A. Wagner, S. Aubrey Stoch	30
14	Effect of Low-, Moderate-, and High-Fat Meals on Raltegravir Pharmacokinetics 2010 ·The Journal of Clinical Pharmacology ·Diana M. Brainard, Evan Friedman, Bo Jin, Sheila Breidinger, (unknown), Larissa Wenning, Julie A. Stone, Jeffrey Chodakewitz, John A. Wagner, Marian Iwamoto	44
15	A Single Supratherapeutic Dose of Vorinostat Does Not Prolong the QTc Interval in Patients with Advanced Cancer 2009 ·Clinical Cancer Research ·Pamela N. Münster, Eric H. Rubin, Simon Van Belle, Evan Friedman, (unknown), Kristien Van Dyck, Xiadong Li, (unknown), (unknown), John A. Wagner, Marian Iwamoto	35
16	Abstract #3604: A phase I single-rising dose study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of an oral akt inhibitor in healthy male volunteers 2009 ·Cancer Research ·Michele Trucksis, Evan Friedman, Adekemi Taylor, Liliana Delgado, Tom Reynders, (unknown), Yingwen Dong, I. Fu, (unknown), Jeffrey Chodakewitz, Marian Iwamoto, (unknown)	4
17	Effect of Different Durations of Ketoconazole Dosing on the Single‐Dose Pharmacokinetics of Midazolam: Shortening the Paradigm 2009 ·The Journal of Clinical Pharmacology ·S. Aubrey Stoch, Evan Friedman, A. Maes, Ka Lai Yee, Yang Xu, Patrick Larson, Maria Fitzgerald, J Chodakewitz, John A. Wagner	38
18	Lack of a Clinically Important Effect of Moderate Hepatic Insufficiency and Severe Renal Insufficiency on Raltegravir Pharmacokinetics 2009 ·Antimicrobial Agents and Chemotherapy ·Marian Iwamoto, William D. Hanley, Amelia S. Petry, Evan Friedman, James Kost, Sheila Breidinger, Kenneth C. Lasseter, Richard A. Robson, N M Lunde, Larissa Wenning, Julie A. Stone, John A. Wagner	37
19	PIII-54An open-label, randomized, 2-period, crossover study, to assess the effects of montelukast on the pharmacokinetics of rosiglitazone, a CYP2C8 substrate, in healthy adults 2006 ·Clinical Pharmacology & Therapeutics ·Evan Friedman, Rohini Ramakrishnan, Patrick Larson, Ken Korzekwa, J. Richard Wagner, Elizabeth Migoya	1
20	A Study to Determine the Effects of Food and Multiple Dosing on the Pharmacokinetics of Vorinostat Given Orally to Patients with Advanced Cancer 2006 ·Clinical Cancer Research ·Eric H. Rubin, Nancy Agrawal, Evan Friedman, (unknown), Kathryn Mazina, Linda Sun, Lihong Du, Justin L. Ricker, Stanley R. Frankel, Keith Gottesdiener, John A. Wagner, Marian Iwamoto	94

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact